Applied Research Program, National Cancer Institute, Bethesda, MD 20892-7344, USA.
J Clin Oncol. 2011 Oct 20;29(30):4045-53. doi: 10.1200/JCO.2011.36.2954. Epub 2011 Sep 19.
PURPOSE: Because adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population has emerged as a priority area. To identify current trends in AYA care, we examined patterns of clinical trial participation, time to treatment, and provider characteristics in a population-based sample of AYA patients with cancer. METHODS: Using the National Cancer Institute Patterns of Care Study, we used multivariate logistic regression to evaluate demographic and provider characteristics associated with clinical trial enrollment and time to treatment among 1,358 AYA patients with cancer (age 15 to 39 years) identified through the Surveillance, Epidemiology, and End Results Program. RESULTS: In our study, 14% of patients age 15 to 39 years had enrolled onto a clinical trial; participation varied by type of cancer, with the highest participation in those diagnosed with acute lymphoblastic leukemia (37%) and sarcoma (32%). Multivariate analyses demonstrated that uninsured, older patients and those treated by nonpediatric oncologists were less likely to enroll onto clinical trials. Median time from pathologic confirmation to first treatment was 3 days, but this varied by race/ethnicity and cancer site. In multivariate analyses, advanced cancer stage and outpatient treatment alone were associated with longer time from pathologic confirmation to treatment. CONCLUSION: Our study identified factors associated with low clinical trial participation in AYA patients with cancer. These findings support the continued need to improve access to clinical trials and innovative treatments for this population, which may ultimately translate into improved survival.
目的:由于过去二十年青少年和年轻成人(AYA)癌症患者的生存率有所提高,因此提高该人群的癌症护理质量和及时性已成为优先事项。为了确定 AYA 护理的当前趋势,我们在基于人群的 AYA 癌症患者样本中检查了临床试验参与,治疗时间和提供者特征的模式。
方法:使用国家癌症研究所的模式护理研究,我们使用多变量逻辑回归来评估人口统计学和提供者特征与通过监测,流行病学和最终结果计划确定的 1358 名 AYA 癌症患者(年龄在 15 至 39 岁之间)的临床试验登记和治疗时间之间的关联。
结果:在我们的研究中,14%的 15 至 39 岁的患者参加了临床试验;参与率因癌症类型而异,急性淋巴细胞白血病(37%)和肉瘤(32%)的参与率最高。多变量分析表明,未投保,年龄较大的患者以及由非儿科肿瘤学家治疗的患者参加临床试验的可能性较小。从病理确诊到首次治疗的中位时间为 3 天,但这因种族/族裔和癌症部位而异。在多变量分析中,晚期癌症和仅门诊治疗与从病理确诊到治疗的时间延长有关。
结论:我们的研究确定了与 AYA 癌症患者临床试验参与率低相关的因素。这些发现支持继续为该人群提供更多的临床试验和创新治疗方法的需求,这最终可能会转化为生存率的提高。
J Natl Cancer Inst. 2014-10-9
Med Res Arch. 2024-1
J Adolesc Young Adult Oncol. 2011-3
Clin Cancer Res. 2010-12-15
J Clin Oncol. 2010-3-8
Eur J Oncol Nurs. 2009-7
Semin Oncol. 2009-6